Welcome to our dedicated page for Telomir Pharms SEC filings (Ticker: TELO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures, offering a structured view of how this preclinical-stage biotechnology company reports its progress and corporate events. Telomir’s filings show that it is a Florida corporation with common stock listed on The Nasdaq Stock Market LLC under the symbol TELO, and they document its focus on developing Telomir-1, a small-molecule therapy targeting epigenetic and metabolic mechanisms in cancer and age-related disease.
For Telomir, Form 8‑K current reports are especially informative. Recent 8‑Ks include Item 8.01 disclosures of new preclinical data, such as Telomir-1’s effects on PSA levels in prostate cancer cells, tumor growth and metastasis in triple-negative breast cancer models, cytotoxicity in leukemia cells, and reductions in intracellular iron compared with the iron chelator Deferoxamine. Another 8‑K details completion of GLP toxicology and safety pharmacology studies in rat and dog models, noting that Telomir-1 was generally well tolerated with no treatment-related adverse or dose-limiting toxicities observed.
Filings also cover corporate and governance matters. Examples include an 8‑K describing a director resignation, compensation committee actions regarding the chief executive officer’s incentives, and a Nasdaq notice related to the timing of the company’s annual shareholder meeting under Listing Rule 5620(a). An additional 8‑K outlines a binding Letter of Intent to acquire TELI Pharmaceuticals, Inc., intended to consolidate worldwide intellectual property and development rights to Telomir-1 within a single public company structure.
On Stock Titan, these filings are supplemented by AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand the implications of GLP safety data, oncology study updates, compensation decisions, and Nasdaq communications. Users can review real-time updates from EDGAR, examine narrative descriptions of Telomir-1’s preclinical profile, and track how Telomir reports its IND-enabling activities and strategic transactions over time.
Telomir Pharmaceuticals, Inc. reported new preclinical in vitro results for its investigational compound Telomir-1 (Telomir-Zn) in human triple-negative breast cancer (TNBC) cell lines. Telomir-Zn showed near-complete tumor cell mortality at 72 hours in the MDA-MB-468 model and significant partial reductions in viable tumor cells in the HCC70 and MDA-MB-231 models.
The company also found that adding supplemental iron reduced Telomir-Zn–induced tumor cell mortality, which it interprets as supporting an iron-dependent mechanism consistent with previously disclosed intracellular metal-modulating activity. Additional TNBC lines (BT-549 and HCC1806) are under evaluation, and a TNBC mouse xenograft study is being prepared in a mammalian system.
Telomir referenced earlier zebrafish xenograft work where Telomir-Zn achieved statistically significant reductions in tumor growth and metastasis in select TNBC models. It reiterated that it is continuing IND-enabling activities and anticipates submitting an Investigational New Drug application in the first quarter of 2026, after previously completing GLP safety and toxicology studies in rats and dogs without treatment-related adverse toxicity.
Telomir Pharmaceuticals, Inc. shareholder John Paul DeJoria, as trustee of the John Paul DeJoria Family Trust and in his individual capacity, reports beneficial ownership of 3,245,000 shares of common stock, representing 9.438% of the class. He has sole power to vote and dispose of all these shares, with no shared voting or dispositive power. The filing states that the securities were not acquired and are not held for the purpose of changing or influencing control of Telomir, indicating a passive investment intent under the Schedule 13G framework.
Telomir Pharmaceuticals, Inc. reported new preclinical cellular data on its lead investigational compound Telomir-1, studied as Telomir-Zn. In collaboration with Smart Assays Biotechnologies, Telomir-Zn was shown to rapidly and dose-dependently increase intracellular zinc and reduce labile ferrous iron within about 30 minutes, with effects sustained for two hours and without loss of cell viability.
The coordinated metal redistribution suggests a potential mechanism that may lower oxidative stress and support genomic and epigenetic stability, processes implicated in both cancer and aging. The company is advancing additional preclinical programs in triple-negative breast cancer and longevity models and currently plans to submit an Investigational New Drug application in the first quarter of 2026.
Telomir Pharmaceuticals is asking stockholders to approve a merger with private company TELI Pharmaceuticals and several related governance and compensation items at a fully virtual annual meeting on March 23, 2026. The key proposal would authorize issuing Telomir common stock and other securities for the merger under Nasdaq Listing Rule 5635(a).
Under the Merger Agreement, a Telomir subsidiary will merge into TELI, which will become a wholly owned subsidiary. The exchange ratio is based on Moore Financial Consulting valuations of TELI at $126.8 million and Telomir at $101.1 million, and the total Telomir shares issued in the merger will not exceed the number of Telomir shares outstanding at closing. Immediately after closing, pre‑merger Telomir holders and pre‑merger TELI holders are each expected to own about 50% of Telomir on a non‑diluted basis.
Other proposals include electing four directors, ratifying Salberg & Company, P.A. as auditor for the year ending December 31, 2025, amending the 2023 Omnibus Incentive Plan, reducing the quorum requirement in the bylaws, approving option grants to non‑executive directors, and allowing adjournment to solicit more proxies if needed. The board unanimously recommends voting “FOR” all seven proposals and notes that merger approval is a closing condition. As of January 23, 2026, Telomir had 34,380,971 common shares outstanding and the stock closed at $1.18 on February 3, 2026.
Telomir Pharmaceuticals, Inc. is asking stockholders to approve a stock-for-stock merger with privately held TELI Pharmaceuticals, Inc., along with several related governance and compensation items, at a fully virtual annual meeting on March 16, 2026. The key item is approval to issue Telomir common stock and other securities in the Merger in an amount exceeding 20% of Telomir’s pre‑merger shares, as required by Nasdaq rules. A Telomir subsidiary will merge into TELI, making TELI a wholly owned subsidiary, with an exchange ratio based on independent valuations by Moore Financial Consulting. Immediately after closing, pre‑merger Telomir holders are expected to own about 50% of the combined company on a non‑diluted basis and TELI holders about 50%, shifting to roughly 41%/59% on a fully diluted basis after giving effect to 14,250,000 TELI warrants tied to FDA acceptance of an IND for Telomir‑1. Existing Telomir stockholders keep their current shares, Telomir remains Nasdaq‑listed under “TELO”, and the current CEO and CFO and four‑member board are expected to continue. The proxy statement highlights extensive risks, including TELI’s pre‑revenue status, Telomir’s funding needs, dependence on Telomir‑1, licensing and related‑party conflicts, regulatory uncertainty and potential dilution from the merger and warrants.
Telomir Pharmaceuticals, Inc. disclosed that Nasdaq has notified the company it is not in compliance with Nasdaq Listing Rule 5620(a), which requires listed companies to hold an annual shareholder meeting within twelve months after the end of their fiscal year. The company had planned to hold its annual meeting on December 30, 2025, but its preliminary proxy statement remains under SEC review.
Nasdaq’s notice does not immediately affect the listing or trading of Telomir’s common stock on the Nasdaq Capital Market. Telomir has until February 23, 2026 to submit a plan to regain compliance, and Nasdaq may grant additional time if it accepts that plan. After the SEC review is completed, Telomir expects to promptly hold its annual meeting and regain compliance and states it intends to take all necessary steps within the applicable cure period.
Telomir Pharmaceuticals reported new incentive arrangements for its Chief Executive Officer, Erez Aminov. Following a review of 2025 performance, the Compensation Committee approved a 2025 short‑term incentive payout of $400,000, based on operational execution, financing activities, and program advancement.
The Board also granted a $150,000 milestone award that will be paid only if the FDA accepts the Company’s future IND submission for its Telomir‑1 program; no IND has been submitted yet. In connection with the potential acquisition of TELI Pharmaceuticals, Inc., the Board approved a transaction advisory award equal to 3% of the total TELI transaction value, payable in cash, equity, or a mix, at the CEO’s election, with any equity vesting immediately at closing. In addition, the CEO’s base salary was set at $500,000 effective January 1, 2026, based on external benchmarking and advice from an independent compensation consultant.
Telomir Pharmaceuticals, Inc. reported favorable results from a full package of Good Laboratory Practice toxicology and safety pharmacology studies for its lead candidate, Telomir-1 (Zn-Telomir). The completed cardiovascular, respiratory, phototoxicity, and repeat-dose studies in in vitro systems and in rat and dog models showed Telomir-1 was generally well tolerated, with no treatment-related adverse or dose-limiting toxicities and only limited, reversible, non-adverse findings. In non-rodent dog studies, no test-article-related changes in blood pressure, heart rate, ECG parameters, or body temperature were seen after oral dosing, and oral studies showed consistent systemic exposure.
These results support advancement into first-in-human clinical trials, with no findings identified that would prevent clinical entry, subject to regulatory pathways. The company plans to submit an Investigational New Drug application in the first quarter of 2026 and aims to start first-in-human clinical studies in the first half of 2026 while continuing preclinical work in oncology and age-related diseases and preparing manuscripts and scientific conference submissions.
Telomir Pharmaceuticals, Inc. (TELO) announced new preclinical data on its investigational candidate Telomir-1 in prostate cancer models. In an in vitro study using androgen-responsive human prostate cancer LNCaP cells, Telomir-1 reduced prostate-specific antigen (PSA) levels in a dose-related manner. PSA is an FDA-recognized biomarker where higher levels generally indicate more active tumor behavior.
The company also highlighted prior mouse data in a PC3 xenograft model of aggressive, non-androgen-related prostate cancer, where Telomir-1 reduced tumor volume as a single agent, and in combination with paclitaxel achieved full tumor volume reduction without treatment-related mortality, while paclitaxel alone caused high mortality. Telomir continues preclinical development of Telomir-1 across oncology, aging biology, autism-related pathways and other age-associated conditions, and is advancing IND-enabling work toward a planned IND submission.
Telomir Pharmaceuticals, Inc. reported that Board member Craig Eagle resigned from the Board of Directors, effective November 14, 2025. The company states that his resignation was not due to any disagreement with Telomir, its management, or any other Board member. The Board expressed appreciation for his service. A copy of Mr. Eagle’s resignation letter is included as Exhibit 17.1 to this report.